{"id":"W3203793933","doi":"10.1016/j.annonc.2021.08.1040","title":"518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"EMD Serono; Genentech; Sierra Oncology; PharmaMar; Eisai; G1 Therapeutics; MacroGenics; Silverback Therapeutics; Astex Pharmaceuticals; Ribon Therapeutics; Syndax Pharmaceuticals; Pfizer; Innovent Biologics; Incyte; NuCana; Daiichi Sankyo Europe; Calithera Biosciences; Mersana Therapeutics; Amgen; Radius Health; Deciphera Pharmaceuticals; Jounce Therapeutics; Ipsen; Five Prime Therapeutics; Merck KGaA; Puma Biotechnology; Regeneron Pharmaceuticals; Plexxikon; Seagen; Relay Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Tolerability; Solid tumor; Pharmacology; Oncology; Internal medicine; Adverse effect; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004041506,0.0001491013,0.0009106507,0.0000889635,0.00002142573,0.000002129398,0.00003810979,0.0002159127,0.000005688305],"category_scores_gemma":[0.0005336361,0.0001330691,0.00007041646,0.0002358636,0.0003656022,0.00007810225,0.0001137573,0.0003770833,3.469307e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007239389,"about_ca_system_score_gemma":0.000690577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008112608,"about_ca_topic_score_gemma":0.0001574247,"domain_scores_codex":[0.9983054,0.0003092849,0.0005308166,0.0004263576,0.0001918582,0.0002362963],"domain_scores_gemma":[0.9985725,0.000225103,0.0002938799,0.0002380553,0.0005310346,0.0001394752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02964071,0.007909067,0.644585,0.0004062644,0.0003645456,0.000366413,0.0009658535,0.0001003856,0.0149251,0.00003749688,0.0003446767,0.3003545],"study_design_scores_gemma":[0.006829621,0.02614765,0.9129884,0.0002372634,0.00007673188,0.00004006703,0.00007813943,0.00007697611,0.05312493,0.00009753898,0.0001879013,0.0001148174],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974753,0.0004410973,0.00002340482,0.001105859,0.00008803022,0.0005217383,0.00002273696,0.00001073911,0.0003110816],"genre_scores_gemma":[0.9987759,0.0001876045,0.0006641836,0.0002955318,0.00002043932,0.00001817553,0.00001270574,0.00001535674,0.00001008805],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3002397,"threshold_uncertainty_score":0.54264,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03554816202193303,"score_gpt":0.3668076639738672,"score_spread":0.3312595019519342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}